ArticleDiscover oncology2026
The influence of the secretome from human amniotic mesenchymal stem cells on p53 and MDM2 expression in MDA-MB-231 breast cancer cell line.
Article in Discover oncology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
purposeBreast cancer ranks as the foremost cause of death among women worldwide. Despite the availability of various treatment options such as chemotherapy, radiotherapy, and hormone therapy, these current strategies are often ineffective and thereby, there is a constant necessity to explore new therapeutic avenues with minimal side effects and enhanced efficacy. The application of cell-based therapy and the use of stem cells or their derivatives in treating diseases, including cancer, have become well established. Herein, we aimed to investigate the impact of the secretome of human amniotic mesenchymal stem cells (hAMSCs) on MDA-MB-231 cancer cells (with a mutant p53 R280K background) focusing on the p53/MDM2/p21/ATM/ATR/PUMA/Bax/Caspase3 signaling pathways. MATERIALS AND
methodsTo achieve this, we developed a co-culture system utilizing 6 well plates transwell. After 72 h, cell death and cell cycle arrest in hAMSCs-treated MDA-MB-231 cells were assessed by analyzing the aforementioned signaling pathways using Western blot and flow cytometry. The exposure time for MTT assay was 48 h, and for DAPI staining, it was 24 h.
resultsOur results revealed an increase in the expression levels of ATM, ATR, CHK2, p53, p-p53, PUMA, Bax, cleaved caspase 3, p21, RB, and p-RB, alongside a reduction in MDM2 expression.
conclusionsThese findings suggest that hAMSCs secretome promotes cell death and induces S phase cell cycle arrest in MDA-MB-231 cells, suggesting its potential as a novel approach in cancer therapy.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.